Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Biomed Mater Res A ; 109(7): 1136-1146, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-32985066

RESUMEN

Ability of high molecular weight (HMW) κ- and λ-carrageenans of the red marine algae Chondrus armatus and their low molecular weight degradation products (LMWDPs) (0.7-20 and 10-170 kDa respectively) to influence functional properties (motility and phagocytosis) of murine peritoneal macrophages was assessed in this study as an in vitro and a weeklong feeding experiment. We demonstrated that, with an exception of one, all carrageenan samples at 100 µg/ml increased cellular motility and dose-dependently decreased phagocytic activity; LMWDPs of λ-carrageenan suppressed motility and had no effect on phagocytosis. Oral administration of all the carrageenan samples at 100 µg/kg/day for 7 days to mice had no effect on their clinical appearance, body weight, weight of their liver, spleen or thymus or development of noticeable changes to their inner organs. All samples induced a shift of the cell composition of the peritoneal cavity towards macrophages. Consumption of LMWDPs of κ-carrageenan resulted in development of leukopenia, however, no changes to relative WBC count were introduced by either of the samples. All samples decreased murine peritoneal macrophages phagocytic activity, with λ-samples possessing higher efficacy than their κ-counterparts; all LMWDPs stimulated peritoneal macrophages motility, with κ-samples possessing higher efficacy than their λ-counterparts In conclusion, we have shown that κ- and λ-carrageenans of the C. armatus and their LMWDPs suppress phagocytotic activity of peritoneal macrophages under both in vitro and in vivo conditions. This allows them to be viewed as pharmacologically active substances andpropagates the need for their further investigation as such.


Asunto(s)
Carragenina/farmacología , Chondrus/química , Factores Inmunológicos/farmacología , Macrófagos/efectos de los fármacos , Fagocitosis/efectos de los fármacos , Animales , Carragenina/administración & dosificación , Carragenina/química , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Factores Inmunológicos/administración & dosificación , Factores Inmunológicos/química , Macrófagos/inmunología , Ratones
2.
J Biomed Mater Res A ; 108(2): 254-266, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31606930

RESUMEN

Antitumor and immunotropic effects of κ-, λ-carrageenan from red marine algae Chondrus armatus and their low-molecular weight (LMW) degradation products were explored. Effects on human esophageal cancer cell lines KYSE30 and FLO1 viability and ability to induce production of pro- and anti-inflammatory cytokines by human monocytes was assessed. All polysaccharides demonstrated antimetabolic and cytostatic activity towards cancer lines, with high-molecular weight carrageenans possessing higher antimetabolic and lower cytostatic activity than their LMW degradation products. All carrageenans induced monocytes to produce pro-inflammatory cytokines IL1ß, IL6, IL18, and TNFα. However, secretion of anti-inflammatory cytokine IL10 was induced only by LMW λ-carrageenan, which exhibited the highest cytokine production inducing efficacy overall. We demonstrate that LMW carrageenan degradation products not only retain biological activity of their precursors, but also increase their efficacy in type-dependent manner, allowing for their future development for pharmacological practice.


Asunto(s)
Antineoplásicos/farmacología , Carragenina/farmacología , Chondrus/química , Factores Inmunológicos/farmacología , Antiinflamatorios/química , Antiinflamatorios/farmacología , Antineoplásicos/química , Carragenina/química , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Citocinas/metabolismo , Humanos , Factores Inmunológicos/química , Monocitos/efectos de los fármacos , Monocitos/metabolismo , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA